Smooth Drug Development May 2025 News Release

Monthly News – May 2025

At Smooth Drug Development, we are excited to share the latest updates and achievements from May 2025:

New Projects

We are pleased to announce progress on key collaborations:

• We signed a contract for medical writing services in a Phase III trial with Brentuximab Vedotin.
• An agreement for medical writing support in a Phase III trial for Coagulation Factor VIII + von Willebrand Factor was signed.
• A contract for medical writing services in a BE study of Mometasone + Azelastine was prepared.

Clinical and Scientific Departments News:

Our clinical teams continue to deliver strong progress across multiple studies:

• Phase I Ophthalmology Trial: Two sites initiated and ready for patient enrollment.
• Dermatology Dose-Finding Study: Enrollment completed for the Cetirizine gel trial.
• Phase III Immunoglobulin Trial: Site visits completed; preparing responses to regulatory comments.
• Women’s Health Phase III Trial: Site selection visits underway for Diindolylmethane study.
• Pregnancy Observational Study: All patients completed follow-up.
• Phase I Metabolic Disorder Trial: Received CTA approval in Belarus.

Business Development News:

Our BD team is expanding partnerships and exploring new opportunities:

• Visited 3 Chinese Pharma companies in May 2025.
• Participated in DIA China 2025 and Sirius University events.
• Featured interview with our Business Development Director at the World Vaccine Congress 2025 (Washington, D.C.).
• Watch the interview here.